Articles

Vol. 1 No. 2 (2026): Issue 2

The Relationship Between pks⁺ Escherichia coli and Colorectal Cancer: A Review

Bolor Ulziitsogt, Chuluunbileg Batbold, Tsogdulam Sumiyabazar, Gantogtokh Dashjamts, Yumchinsuren Tsedendorj, Tegshjargal Badamjav, Ganchimeg Dondov, Tulgaa Lonjid, Batbold Batsaikhan
1-11

Long-Term Shifts and Disparities in Colorectal Cancer Mortality in the United States: A Population-Based Analysis (1999–2023)

Mahmoud Tablawy, Alyaa Ahmed Ibrahim, Salma Ehab, Mohammad Rayyan Faisal, Maryam Saghir, Eshal Saghir, Abdelrhman H. Mohamed, Rodina Sharaf, Ahmed Atef Mohamed, Humam Al-Machtomi, Mina Nageh, Mohaimen Mohammed Al-Machtomi, Ahmed Tharwat Emara, Safeya Fawzi, Ahmed Ebrahim, Mahdi Ahmed, Amro Ali, Mohamed Fawzi Hemida
12-21

National Trends in Pancreatic Cancer-Related Mortality: A Population-Based Analysis of Rural–Urban Disparities and the Distribution of Place of Death

Zuha Tariq, Alyaa Ahmed Ibrahim, Ahmed Khairy, Mohammad Rayyan Faisal, Abdelrahman Aly Mohamed, Rahemeen Goraya, Mahmoud Tablawy, Ibtissam ElGhazzani, Mohamed Ibrahim, Sihame ElGhazzani, Mahdi Ahmed, Ilhame ElGhazzani, Mohamed Zabady, Ahmed Atef Mohamed, Yara Refaii, Mohamed Fawzi Hemida
22-27

Suspected Pembrolizumab-Associated Encephalitis Presenting as Altered Mental Status in an Elderly Patient with Cancer: A Case Report

Layal Ezzeddine, Hazem Abosheaishaa, Rajab Abdulsadek
28-35

Vol. 1 No. 1 (2026): Issue 1

Early clinical signals for Placental Mesenchymal Stem Cell Hydrogel in Radiation-induced Skin Injury

Fatma A. Rikabe, Abdelrhman Gouda, Abdelrhman H. Mohamed, Sampana Fatima
1-3

Sepsis Mortality Among Patients with Myeloid Leukemia in the United States, 1999–2023: Insights, Trends, and Disparities

Alyaa Ahmed Ibrahim, Mahmoud Tablawy, Mohamed Fawzi Hemida, Anika Goel, Raveen Mujeeb, Krish Patel, Sahil Jairamani, AbdAllah Dewair, Mirna Hussein, Maryam Saghir, Eshal Saghir, Safeya Fawzi, Ehsanullah Alokozay, Amro Ali
4-12

Antibody-Drug Conjugates in Solid Tumors: Mechanisms, Clinical Advances, and Emerging Resistance Patterns

Hassan A. Abdou, Shadi Awny
13-20

Late Gastrointestinal and Genitourinary Progression of Metastatic Invasive Lobular Breast Carcinoma: A Case Report

Navin Roger Prasad, Stanley M Nwabudike, David Brian Meredith, Vipin Mittal
21-27

Federated Hybrid CNN Vision Transformer Framework for Breast Cancer Classification Under Simulated Non-IID Settings

Bandhan Panda, Bibek Kumar Patro, Siba Sundar Das, Santosh Kumar Kar
28-37

Divergent Temporal Trends in Site-Specific Sarcoma Mortality in the United States, 1999–2020: A Population-Based Analysis

Muhanad Alzahrani, Abdullah Alabbasi, Mohammed Sayes, Rayyan Fahad H Altemani, Ziyad Alzahrani
38-43

ASIDE Oncology at a glance

What does it publish?
Original research, reviews, clinical case studies and commentary across all subspecialties of oncology.
Does it cost anything?
No. No submission fee, no article processing charge and no publication fee, at any stage.
How is peer review done?
An editor screens each manuscript for scope, ethics, reporting standards and similarity; it then goes to double-anonymous peer review.
Is it open access?
Yes. Every article is free to read on publication under a CC BY 4.0 licence, with a Crossref DOI.
Where is it indexed?
Not yet listed in DOAJ, PubMed or Scopus. ISSN 3069-9967.
How do I submit?
Read the author guidelines, then submit online. Questions? Our Help Center starts here.

About the Journal

ASIDE Oncology is a peer-reviewed, open-access journal for clinicians and researchers in oncology and haematology. There is no fee to submit and no fee to publish.

The journal is published and owned by PubPorta Publishing LLC, 16192 Coastal Highway, Lewes, Delaware 19958, USA. Academic oversight and scholarly guidance are provided by the American Society for Inclusion, Diversity, and Equity in Healthcare (ASIDE).

What we publish

Original research, case reports, systematic reviews and clinical images across oncology and haematology. We welcome work on health equity, the social determinants of health and access to care for under-served populations.

Why authors choose ASIDE Oncology

  • No article processing charge: submission, peer review and publication are free for every author
  • Double-anonymous peer review
  • Immediate open access under CC BY 4.0
  • A Crossref DOI for every article

Read the call for submissions or see the author guidelines.

ISSN (Print) 3069-9959 · ISSN (Online) 3069-9967

Announcements

Current Issue

Vol. 1 No. 2 (2026): Issue 2
View Vol. 1 No. 2 (2026): Issue 2
DOI: https://doi.org/10.71079/ASIDE.Onc.1.2
Published: 2026-09-01

Original Article

Review Article

Case Report

View All Issues